RNA, U6 small nuclear 485, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-485P profile across patient tissues and cancer cell-line models. RNU6-485P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RNU6-485P is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, RNU6-485P RNA expression shows 13,288 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KICH, and TGCT as cancer lineages where RNU6-485P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-485P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-485P survival associations across molecular data types. RNU6-485P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-485P RNA expression–survival associations across cancer types. High RNU6-485P expression shows unfavorable associations in DLBC and UVM, but favorable associations in KIRP, KIRC, SKCM and READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RNU6-485P RNA expression.
This table summarizes RNU6-485P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-485P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-485P shows lower tumor expression in KICH, LUSC, KIRP and COAD and higher tumor expression in KIRC. The KICH box plot shows higher RNU6-485P RNA expression in normal versus tumor tissue (log2 FC = −1.457, t-test p < 0.001).
This table shows molecular features associated with RNU6-485P in patient tissues and cancer cell lines. In patient samples, RNU6-485P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
